Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study

被引:0
作者
Ye Seul Bae
Jooyoung Chang
Sang Min Park
机构
[1] Seoul National University Hospital,Department of Family Medicine
[2] Seoul National University Graduate School,Department of Biomedical Sciences
[3] Seoul National University College of Medicine,Department of Biomedical Sciences
来源
Archives of Osteoporosis | 2019年 / 14卷
关键词
Epidemiology; Bisphosphonate; Female breast cancer; Ovarian cancer; Cervical cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 141 条
[1]  
Lewiecki EM(2010)Bisphosphonates for the treatment of osteoporosis: insights for clinicians Ther Adv Chronic Dis 1 115-128
[2]  
Clézardin P(2005)Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity Cancer Res 65 4971-4974
[3]  
Ebetino FH(2000)Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 2949-2954
[4]  
Fournier PG(2006)Molecular mechanisms of action of bisphosphonates: current status Clin Cancer Res 12 6222s-6230s
[5]  
Boissier S(2010)Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk Br J Cancer 102 799-802
[6]  
Ferreras M(2012)Exposure to oral bisphosphonates and risk of cancer Int J Cancer 131 E717-E725
[7]  
Peyruchaud O(2010)Oral bisphosphonate use and breast cancer incidence in postmenopausal women J Clin Oncol 28 3582-3590
[8]  
Magnetto S(2011)Use of bisphosphonates and risk of breast cancer Calcif Tissue Int 88 255-262
[9]  
Ebetino FH(2017)Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies Pharmacoepidemiol Drug Saf 26 1286-1295
[10]  
Colombel M(2011)Bisphosphonate use after estrogen receptor–positive breast cancer and risk of contralateral breast cancer J Natl Cancer Inst 103 1752-1760